IDO1 in cancer: a Gemini of immune checkpoints

• Published in: Cellular & molecular immunology Vol. 15; no. 5; pp. 447 - 457
• Main Authors: Zhai, Lijie, Ladomersky, Erik, Lenzen, Alicia, Nguyen, Brenda, Patel, Ricky, Lauing, Kristen L, Wu, Meijing, Wainwright, Derek A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.05.2018; Nature Publishing Group
• Subjects: Amino acids; Animals; Antibodies; Biomedical and Life Sciences; Biomedicine; Brain cancer; Cancer; Catabolites; Clinical trials; Clinical Trials as Topic; Dioxygenase; Enzymatic activity; Enzymes; Glioma; Humans; Immune checkpoint; Immune Evasion; Immunology; Immunosuppressive agents; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism; Lymphocytes T; Medical Microbiology; Metastases; Microbiology; Review; Review Article; Transcription; Tryptophan; Tryptophan - metabolism; Tumor Microenvironment; Vaccine; glioblastoma; IDO; immunotherapy; Treg; glioma; immunosuppression; melanoma; kynurenine
• ISSN: 1672-7681; 2042-0226
• DOI: 10.1038/cmi.2017.143

Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that converts the essential amino acid tryptophan (Trp) into downstream catabolites known as kynurenines. Coincidently, numerous studies have demonstrated that IDO1 is highly expressed in multiple types of human cancer. Preclinical studies have further introduced an interesting paradox: while single-agent treatment with IDO1 enzyme inhibitor has a negligible effect on decreasing the established cancer burden, approaches combining select therapies with IDO1 blockade tend to yield a synergistic benefit against tumor growth and/or animal subject survival. Given the high expression of IDO1 among multiple cancer types along with the lack of monotherapeutic efficacy, these data suggest that there is a more complex mechanism of action than previously appreciated. Similar to the dual faces of the astrological Gemini, we highlight the multiple roles of IDO1 and review its canonical association with IDO1-dependent tryptophan metabolism, as well as documented evidence confirming the dispensability of enzyme activity for its immunosuppressive effects. The gene transcript levels for IDO1 highlight its strong association with T-cell infiltration, but the lack of a universal prognostic significance among all cancer subtypes. Finally, ongoing clinical trials are discussed with consideration of IDO1-targeting strategies that enhance the efficacy of immunotherapy for cancer patients.